Raphael Pharmaceutical Inc. (RAPH) — SEC Filings
Raphael Pharmaceutical Inc. (RAPH) — 15 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 6 10-Q, 6 8-K, 2 10-K.
View Raphael Pharmaceutical Inc. on SEC EDGAR
Overview
Raphael Pharmaceutical Inc. (RAPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Raphael Pharmaceutical Inc. (RAPH) reported a net loss of $1.006 million for the nine months ended September 30, 2025, a decrease from the $1.124 million net loss in the same period of 2024. The company's operating loss also decreased to $991 thousand in the first nine months of 2025, down from $1.1
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 12 neutral. The dominant filing sentiment for Raphael Pharmaceutical Inc. is neutral.
Filing Type Overview
Raphael Pharmaceutical Inc. (RAPH) has filed 6 10-Q, 6 8-K, 2 10-K, 1 S-1 with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (15)
Risk Profile
Risk Assessment: Of RAPH's 15 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$1.006M |
| EPS | -$0.05 |
| Debt-to-Equity | N/A |
| Cash Position | $3K |
| Operating Margin | N/A |
| Total Assets | $7K |
| Total Debt | $1.271M |
Key Executives
- Ajay Kumar Dhadha
- Zvi Laufer
- Shlomo Pilo
Industry Context
The pharmaceutical industry is highly competitive and capital-intensive, requiring substantial investment in research and development. Companies often face long development cycles, stringent regulatory hurdles, and patent expirances. Smaller biopharmaceutical companies like Raphael Pharmaceutical Inc. typically rely on external funding to finance their operations and drug development pipelines.
Top Tags
pharmaceutical (6) · 10-Q (4) · Pharmaceuticals (3) · Biotechnology (2) · Going Concern (2) · Net Loss (2) · R&D Expenses (2) · 10-K (2) · acquisition (2) · pipeline (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $3K | Critically low balance as of September 30, 2025, down from $19K at Dec 31, 2024. |
| Net loss | $1.006M | For the nine months ended September 30, 2025, indicating continued unprofitability. |
| Accumulated deficit | $9.895M | As of September 30, 2025, highlighting significant historical losses. |
| Research and development expenses | $286K | For the nine months ended September 30, 2025, a significant decrease from $565K in 2024. |
| General and administrative expenses | $705K | For the nine months ended September 30, 2025, an increase from $550K in 2024. |
| Net cash used in operating activities | $256K | For the nine months ended September 30, 2025, contributing to cash depletion. |
| Net cash provided by financing activities | $240K | For the nine months ended September 30, 2025, insufficient to cover operating burn. |
| Common stock outstanding | 19,626,418 | As of November 13, 2025, reflecting recent share issuances. |
| Accumulated Deficit | $9.64M | Increased from $8.89M at Dec 31, 2024, highlighting ongoing losses. |
| Net Loss (6 months) | $751K | Slightly improved from $798K in the prior year period, but still substantial. |
| R&D Expenses (6 months) | $213K | Decreased significantly from $403K in 2024, potentially impacting product development pace. |
| G&A Expenses (6 months) | $527K | Increased from $393K in 2024, indicating rising administrative costs. |
| Cash & Equivalents | $20K | Minimal cash balance as of June 30, 2025, up from $19K at Dec 31, 2024, but insufficient for long-term operations. |
| Financing Cash Flow (6 months) | $240K | Primary source of funding, indicating reliance on equity raises. |
| Shares Outstanding | 19.63M | Increased from 18.70M at Dec 31, 2024, due to stock and warrant issuances, causing dilution. |
Frequently Asked Questions
What are the latest SEC filings for Raphael Pharmaceutical Inc. (RAPH)?
Raphael Pharmaceutical Inc. has 15 recent SEC filings from Mar 2024 to Nov 2025, including 6 10-Q, 6 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RAPH filings?
Across 15 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 12 neutral. The dominant sentiment is neutral.
Where can I find Raphael Pharmaceutical Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Raphael Pharmaceutical Inc. (RAPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Raphael Pharmaceutical Inc.?
Key financial highlights from Raphael Pharmaceutical Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RAPH?
The investment thesis for RAPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Raphael Pharmaceutical Inc.?
Key executives identified across Raphael Pharmaceutical Inc.'s filings include Ajay Kumar Dhadha, Zvi Laufer, Shlomo Pilo.
What are the main risk factors for Raphael Pharmaceutical Inc. stock?
Of RAPH's 15 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Raphael Pharmaceutical Inc.?
Forward guidance and predictions for Raphael Pharmaceutical Inc. are extracted from SEC filings as they are enriched.